Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | FPR1 | P21462 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25818836 | 0.90 | NLRP3 (0.57) | NLRP3MAPTRXFP1TP53THRB | |
| SCHEMBL23952032 | 0.90 | NLRP3 (0.54) | NLRP3MAPTRXFP1TP53FPR1 | |
| SCHEMBL25818811 | 0.89 | NLRP3 (0.70) | NLRP3MAPTRXFP1TP53THRB | |
| SCHEMBL23952055 | 0.84 | NLRP3 (0.64) | NLRP3MAPTFPR1FPR2ALDH1A1 | |
| SCHEMBL23952369 | 0.83 | NLRP3 (0.79) | NLRP3MAPTRXFP1FPR1FPR2 | |
| SCHEMBL30061337 | 0.83 | NLRP3 (0.79) | NLRP3MAPTRXFP1FPR1FPR2 | |
| SCHEMBL23952195 | 0.80 | NLRP3 (0.56) | NLRP3MAPTRXFP1TP53POLB | |
| SCHEMBL25818872 | 0.79 | NLRP3 (0.55) | NLRP3MAPTRXFP1TP53ALDH1A1 | |
| SCHEMBL23952384 | 0.79 | NLRP3 (0.55) | NLRP3MAPTRXFP1TP53POLB | |
| SCHEMBL23952058 | 0.79 | NLRP3 (0.54) | NLRP3MAPTRXFP1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183248-A1 | PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NLRP1, IL1B | NLRP3 1/4885MAPT 1978/4885RXFP1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.